Menu
Search Close

News

Directorate Change

12th December 2012

Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, announces the resignation of Nigel Evans, a Director on the Company’s Board of Directors and Company Secretary, effective 11 December 2012.

The Board intends to make a new appointment and will make an announcement in due course.

David Evans, Chairman of Scancell, commented: "I would like to thank Nigel for his important contribution to Scancell over many years. Nigel, in his role as Executive Chairman of the Company from 2000-2007 played a critical role in development of the company at a particularly turbulent time in its history. More recently Nigel has given steadfast support to the Company both as Board Director and as Company Secretary and we wish him well in his retirement.

The Directors of the issuer accept responsibility for this announcement.

 

-ENDS-

 

For Further Information:

 

Dr Richard Goodfellow, Joint CEO

Professor Lindy Durrant, Joint CEO

Scancell Holdings Plc

Scancell Holdings Plc

+ 44 (0) 74 2323 0497 

+ 44 (0) 74 2323 0497 

 

Annie Cheng, CFA

Visible Value LLP

+ 44 (0) 74 2323 0497 

 

Camilla Hume/Stephen Keys

Cenkos

+ 44 (0) 20 7397 8900

     

  

About Scancell

Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could have a profound effect on the way that cancer vaccines are developed.

Webcasts, Interviews and Media Coverage

Scancell to begin UK arm of phase II skin cancer trial ‘immediately’

Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date

Mon, 19 Aug 2019 06:46:00

Scancell on verge of recruiting patients with advanced melanoma for UK clinical trials

The immunotherapy specialist gave an update on progress for a “busy and productive” half-year.

Mon, 01 Jul 2019 11:19:00